Amarin_Logo_JPEG.jpg
Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update
30 oct. 2024 16h05 HE | Amarin Corporation plc
 -- Strong Cash Position of $306 Million; 9th Consecutive Quarter of Positive or Neutral Cash Balance ---- Total Net Revenue of $42 Million Represents Continued Source of Cash from the U.S., RoW...
Amarin_Logo_JPEG.jpg
Amarin Announces Two Upcoming Investor Events
01 oct. 2024 08h00 HE | Amarin Corporation plc
-- Company to Report Third Quarter 2024 Financial Results Wednesday, October 30 –- -- Amarin to Hold Virtual Analyst & Investor Day Thursday, November 14 -- DUBLIN and BRIDGEWATER, N.J., Oct. ...
Amarin_Logo_JPEG.jpg
Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting
09 sept. 2024 07h30 HE | Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that new supported and/or funded research on the clinical impact of...
Amarin_Logo_JPEG.jpg
Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress
22 août 2024 08h30 HE | Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced new supported and/or funded subgroup data from the landmark REDUCE-IT®...
Amarin_Logo_JPEG.jpg
Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update
31 juil. 2024 07h00 HE | Amarin Corporation plc
-- Cash Position of $307 Million Provides Stable and Strong Capital Foundation –-- Total Net Revenue of $68 Million ($124 Million Year-To-Date) Reflecting Continuing Efforts to Maximize...
Amarin_Logo_JPEG.jpg
Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal
17 juil. 2024 16h15 HE | Amarin Corporation plc
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease...
Amarin_Logo_JPEG.jpg
Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024
17 juil. 2024 08h00 HE | Amarin Corporation plc
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and...
Amarin_Logo_JPEG.jpg
Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)
08 juil. 2024 07h30 HE | Amarin Corporation plc
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG)...
Amarin_Logo_JPEG.jpg
Amarin Board of Directors Announces CEO Transition
04 juin 2024 07h30 HE | Amarin Corporation plc
-- Board Appoints Aaron Berg as President & CEO -- -- Patrick Holt to Step Down as President & CEO to Pursue Other Opportunities -- DUBLIN and BRIDGEWATER, N.J., June 04, 2024 ...
Amarin_Logo_JPEG.jpg
 Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.
28 mai 2024 08h15 HE | Amarin Corporation plc
-- Greek Ministry of Health approved VAZKEPA® (icosapent ethyl) for national reimbursement to reduce cardiovascular risk in statin-treated adult patients with elevated triglycerides (≥ 150 mg/ml [≥...